Francine Johansson Azeredo

Dr. Francine Johansson Azeredo

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
FAFrancine Johansson Azeredo
Francine Johansson Azeredo
TCTeresa Dalla Costa
Teresa Dalla Costa
HDHartmut Derendorf
Hartmut Derendorf

22 July 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
LPLaiz Campos Pereira
Laiz Campos Pereira
MFMarcelo Aguiar de Fátima
Marcelo Aguiar de Fátima
VSValdeene Vieira Santos
Valdeene Vieira Santos
CBCarolina Magalhaes Brandao
Carolina Magalhaes Brandao
IAIzabel Almeida Alves
Izabel Almeida Alves
FAFrancine Johansson Azeredo
Francine Johansson Azeredo
Pharmacokinetics and pharmacodynamics are areas in pharmacology related to different themes in the pharmaceutical sciences, including therapeutic drug monitoring and different stages of drug development. Although the knowledge of these disciplines is essential, they have historically been treated separately. While pharmacokinetics was limited to describing the time course of plasma concentrations after administering a drug-dose, pharmacodynamics describes the intensity of the response to these concentrations. In the last decades, the concept of pharmacokinetic/pharmacodynamic modeling (PK/PD) emerged, which seeks to establish mathematical models to describe the complete time course of the dose-response relationship. The integration of these two fields has had applications in optimizing dose regimens in treating antibacterial and antifungals. The anti-infective PK/PD models predict the relationship between different dosing regimens and their pharmacological activity. The reviewed studies show that PK/PD modeling is an essential and efficient tool for a better understanding of the pharmacological activity of antibacterial and antifungal agents.

Verified
Journal Article
Open access
PDF file
MSMariana Barros de Cerqueira Silva
Mariana Barros de Cerqueira Silva
BPBiane Philadelpho
Biane Philadelpho
JSJohnnie Santos
Johnnie Santos
VSVictória Souza
Victória Souza
CSCaio Souza
Caio Souza
Ederlan Souza FerreiraEderlan Souza Ferreira
Ederlan Souza Ferreira
In this study, in silico approaches are employed to investigate the binding mechanism of peptides derived from cowpea β-vignin and HMG-CoA reductase. With the obtained information, we designed synthetic peptides to evaluate their in vitro enzyme inhibitory activity. In vitro, the total protein extract and <3 kDa fraction, at 5000 µg, support this hypothesis (95% and 90% inhibition of HMG-CoA reductase, respectively). Ile-Ala-Phe, Gln-Gly-Phe, and Gln-Asp-Phe peptides were predicted to bind to the substrate binding site of HMGCR via HMG-CoAR. In silico, it was established that the mechanism of HMG-CoA reductase inhibition largely entailed mimicking the interactions of the decalin ring of simvastatin and via H-bonding; in vitro studies corroborated the predictions, whereby the HMG-CoA reductase activity was decreased by 69%, 77%, and 78%, respectively. Our results suggest that Ile-Ala-Phe, Gln-Gly-Phe, and Gln-Asp-Phe peptides derived from cowpea β-vignin have the potential to lower cholesterol synthesis through a statin-like regulation mechanism.

1 November 2012 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
FAFrancine Johansson Azeredo
Francine Johansson Azeredo
BABibiana Verlindo de Araújo
Bibiana Verlindo de Araújo
SHSandra Elisa Haas
Sandra Elisa Haas
BTBruna Torres
Bruna Torres
MPMaiara Pigatto
Maiara Pigatto
TCTeresa Dalla Costa
Teresa Dalla Costa
The aims of this study were to evaluate free levels of fluconazole (FCZ) in the kidneys of healthy and Candida albicans -infected Wistar rats using microdialysis and to establish the relationship between free renal and total plasma levels under both conditions. Microdialysis recovery rates were determined in vitro by dialysis, and retrodialysis recovery rates were determined in vivo by retrodialysis. The recovery rate was around 50%, independent of the method, drug concentration, or condition ( in vitro or in vivo ) used. FCZ kidney penetration in healthy and infected rats was investigated after the administration of 10 mg/kg of body weight intravenously (i.v.) or 50 mg/kg orally ( n = 6/group) and blood and microdialysate sample harvesting at predetermined time points up to 24 and 18 h, respectively. There were no statistical differences between the area under the free concentration-time curve (AUC 0–∞ ) values in plasma and in tissue for either healthy or infected groups for the same dose regimen investigated. The antifungal tissue penetrations were similar for both doses and under all conditions investigated (ranging from 0.77 to 0.84). The unbound fraction of FCZ was concentration independent (86.0% ± 2.0%), allowing the prediction of free renal levels using pharmacokinetic parameters obtained from total plasma fitting. The results showed that free renal and free plasma levels are similar in healthy and systemically C. albicans -infected rats. Therefore, free plasma levels are a good surrogate to estimate free FCZ renal concentrations in systemic candidiasis and can be used to optimize dosing regimens for this drug.

8 July 2020 in Drugs in R&D
Verified
Journal Article
Open access
PDF file
TCTatiana Xavier da Costa
Tatiana Xavier da Costa
FAFrancine Johansson Azeredo
Francine Johansson Azeredo
MUMarcela Abbott Galvão Ururahy
Marcela Abbott Galvão Ururahy
MFMiguel Adelino da Silva Filho
Miguel Adelino da Silva Filho
RMRand Randall Martins
Rand Randall Martins
AOAntonio Gouveia Oliveira
Antonio Gouveia Oliveira
Background and Objective The pharmacokinetic basis of magnesium sulphate (MgSO4) dosing regimens for preeclampsia (PE) prophylaxis and treatment is not clearly established. The aim of study is to develop a population pharmacokinetic (PK) model of MgSO4 in PE, and to determine key covariates having an effect in MgSO4 pharmacokinetics in preeclampsia (PE) and to determine key covariates having an effect in MgSO4 PK. Methods A prospective cohort study was conducted from June 2016 to February 2018 in patients with PE administered MgSO4 as a 4-g bolus followed by continuous infusion at a rate of 1 g/h. Serum magnesium concentrations were obtained before treatment administration and 2, 6, 12, and 18 h after the initial dose. The software Monolix was used to estimate population PK parameters of MgSO4 [clearance (CL), volume of distribution (V), half-life] and to develop a PK model with baseline patient demographic, clinical, and laboratory covariates. Results The study population consisted of 109 patients. The PK profile of MgSO4 was adequately described by a one-compartment PK model. The model estimate of the population CL was 1.38 L/h; for V, it was 13.3 L; and the baseline magnesium concentration was 0.77 mmol/L (1.87 mg/dL). The baseline body weight and serum creatinine statistically influenced MgSO4 CL and V, respectively. The model was parameterized as CL and V. Conclusion The PK of MgSO4 in pregnant women with PE is significantly affected by creatinine and body weight. Pregnant women with PE and higher body weight have a higher V and, consequently, a lower elimination rate of MgSO4. Pregnant women with PE and a higher serum creatinine value show lower CL and, therefore, lower MgSO4 elimination rate.

13 January 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MBMatheus Antônio da Hora Borges
Matheus Antônio da Hora Borges
FPFabiolla Rocha Santos Passos
Fabiolla Rocha Santos Passos
JQJullyana de Souza Siqueira Quintans
Jullyana de Souza Siqueira Quintans
FAFrancine Johansson Azeredo
Francine Johansson Azeredo
Despite the several uses of drugs from natural compounds in the pharmaceutical industry, new molecules have been discovered and associated with pharmacological activities over the years. Hecogenin, a steroidal saponin, has been the subject of several studies due to reports of pharmacological activities. This study combines the articles published to date that show the pharmacological activity and the mechanism of action of hecogenin, its acetate, and its derivates. This compilation shows that the compounds can act in different pathologies that affect many systems of the human body. They showed pharmacological properties in inflammation, mediating cytokines, cells, and environment. Also, it participated in tumoral processes by pathways like PPGARγ, ERK½, and MMP-2 and showed antimicrobial effects against organisms like Candida and Aedes aegypti's larvae. This review indicates that continuing studies with these molecules are essential once they have the potential to be a future drug.